Asia Pacific

Europe, Middle East & Africa (EMEA)

Latin America

North America
  • Home
  • Congress & Events
  • Safety, pharmacokinetics, and pharmacodynamics of CT-388, a signal-biased dual GLP-1/GIP receptor agonist, over 24 weeks in adults with obesity

Safety, pharmacokinetics, and pharmacodynamics of CT-388, a signal-biased dual GLP-1/GIP receptor agonist, over 24 weeks in adults with obesity

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Send Via Email

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site Stay on Medically

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically